PATENT CLAIM ANALYSIS

Application Number: 16066427
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "234200"]

Abstract:
The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.

Claim (Index 2):
The compound or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug according to  claim 1 , wherein\n X is C, one of R 1  and R 2  is hydrogen and the other is chloro, and the chloro substituent is replaced at X.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 94.0
- Lexical Diversity: 1.71429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16062399', '13319079', '15534838', '14521766', '15544676']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8208402394811408
- 35 USC 102 Novelty (BERT): 0.6081983101203345
- Combined Prediction Score: 0.7995760465450602
- Mean Citation Score: 419.36657
- Max Citation Score: 604.61755
- Similarity Product: 463.1945795754911

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test